Aptorum Group is now the first biopharmaceutical company listed on the Nasdaq to be admitted to Euronext, with shares trading from 24 July 2020.
The Reed Smith team that advised on the listing was led by Paris based partner Guilain Hippolyte and associate Lucie Guegan. They were supported by London based partner James Wilkinson and associate Fiona McFarlane, and New York based partner Gerry DiFiore and associate Sheran Sharafi.
Hippolyte said: “We are proud to have supported Aptorum Group on its listing on Euronext Paris, which is an important milestone following its successful listing on the Nasdaq. The listing underlines our Global Corporate Group’s in depth understanding of the life sciences industry, particularly in cross-border operations requiring international coordination.”